Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Pharmacology And Immunology Of Botulinum Toxin Serotypes

K. Aoki
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Botulinum toxin preparations can provide patients with a therapeutic modality that may improve both their medical condition and quality of life. The mechanism of action of the various botulinum toxin preparations and serotypes is similar: they all block neurotransmitter release. The majority of clinical conditions treated are based upon the targeted temporary chemodenervation of the selected organ. The antinociceptive effects of botulinum toxin type A (BTX-A), based on preclinical studies and clinical experiences in treating movement disorders and other painful conditions, will also be reviewed to illustrate how this compound may act as it alleviates the discomfort associated with various conditions. Chronic therapies with preparations with the lowest amount of neurotoxin protein provide the best chance for long-term therapy by minimizing the potential of the patient to form neutralizing antibodies. Differences in formulations or serotypes impart unique efficacy and safety profiles and thus does not support a simple dose ratio conversion between products.
This paper references
10.1016/S0304-3940(97)13448-6
Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human
R. Eleopra (1997)
10.1111/j.1469-8749.1994.tb11864.x
BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY
A. Cosgrove (1994)
10.1212/WNL.48.2.456
Dose-dependent, central effects of botulinum neurotoxin type A
B. Moreno-López (1997)
Development of BOTOX ® – Its history and pharmacol
KR Aoki (1998)
Immunogenicity of the neurotoxins of Clostridium botulinum
C. Hatheway (1994)
10.1002/MDS.870110425
Botulinum toxin is unsatisfactory therapy for fibromayalgia
G. Paulson (1996)
Botulinum toxin therapy : basic science and therapeutic overview of other applications
MF Brin (2000)
10.1146/ANNUREV.MICRO.53.1.551
Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.
E. Johnson (1999)
10.1212/WNL.53.7.1431
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
A. Brashear (1999)
10.1523/JNEUROSCI.11-03-00657.1991
Axotomy-like changes in cat motoneuron electrical properties elicited by botulinum toxin depend on the complete elimination of neuromuscular transmission
M. Pinter (1991)
10.1016/S0140-6736(86)92070-2
DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS
J. C. Tsui (1986)
10.1002/ANA.410280407
Treatment of spasticity with botulinum toxin: A double‐blind study
B. Snow (1990)
10.1212/WNL.38.11.1780
Neuromuscular effects distant from the site of botulinum neurotoxin injection
Richard K. OIney (1988)
10.1212/WNL.49.1.189
Human response to botulinum toxin injection: Type B compared with type A
R. Sloop (1997)
10.1111/j.1469-8749.2000.tb00056.x
Analgesic effects of botulinum toxin A: a randomized, placebo‐controlled clinical trial
S. Barwood (2000)
10.1615/CRITREVIMMUNOL.V19.I3.30
Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.
M. Atassi (1999)
10.1128/JCM.35.3.578-583.1997
Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes.
G. Doellgast (1997)
BOTOX ( botulinum toxin type A ) purified neurotoxin complex prepared from the new bulk toxin retains the same preclinical efficacy as the original but with reduced immunogenicity
R Aoki (1999)
Treatment of tension-type headache with botulinum toxin: a pilot study.
W. Schulte-Mattler (1999)
10.1046/j.1526-4610.2000.00066.x
Botulinum Toxin Type A as a Migraine Preventive Treatment
S. Silberstein (2000)
10.1212/WNL.56.10.1290
Botulinum toxin A and chronic low back pain
L. Foster (2001)
10.1002/MUS.880160913
Quantifying how location and dose of botulinum toxin injections affect muscle paralysis
C. M. Shaari (1993)
10.1016/S0304-3940(98)00775-7
Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans
R. Eleopra (1998)
10.1002/MDS.870020402
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M. Brin (1987)
10.1212/wnl.53.7.1431
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
M. Brin (1999)
10.1111/j.1526-4610.1994.hed3408458.x
Tension Headache: Botulinum Toxin Paralysis of Temporal Muscles
J. A. Zwart (1994)
10.1136/jnnp.53.8.633
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
J. Jankovic (1990)
10.1212/WNL.40.8.1213
Double‐blind, placebo‐controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis
P. Greene (1990)
10.1111/j.1468-1331.1999.tb00032.x
Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations
K. Aoki (1999)
10.1111/j.1468-1331.1999.tb00025.x
Botulinum toxin type A injections for myofascial pain syndrome and tension‐type headache
M. Porta (1999)
10.1002/(SICI)1096-9861(19981012)400:1<1::AID-CNE1>3.0.CO;2-D
Effects of botulinum neurotoxin type A on the expression of gephyrin in cat abducens motoneurons
B. Moreno-López (1998)
10.1212/WNL.40.2.277
Botulinum toxin injections for cervical dystonia
J. Jankovic (1990)
10.1002/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8
Extrafusal and intrafusal muscle effects in experimental botulinum toxin‐A injection
R. Rosales (1996)
10.1046/j.1526-4610.1998.3806468.x
Botulinum Toxin A, Adjunctive Therapy for Refractory Headaches Associated With Pericranial Muscle Tension
A. Wheeler (1998)
10.1111/j.1365-2133.1996.tb07974.x
Botulinum A toxin injection in Focal hyperhidrosis
P. Schnider (1996)
10.1002/MDS.870090216
Development of resistance to botulinum toxin type A in patients with torticollis
P. Greene (1994)
10.1016/S0165-2478(97)00124-7
Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc.
M. Oshima (1998)
10.1212/WNL.45.9.1743
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
10.1016/S0021-5155(99)00197-5
[Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles].
H. Ishikawa (2001)
Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. Poster 246.2 Presented at the Society for Neuroscience Annual Meet
ML Cui (2000)
10.1212/WNL.51.5.1494
Botulinum toxin type F for treatment of dystonia
R. Chen (1998)
10.1016/S0006-2952(00)00260-4
Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms.
J. Purkiss (2000)
10.1152/JN.1994.72.4.2041
Botulinum neurotoxin alters the discharge characteristics of abducens motoneurons in the alert cat.
B. Moreno-López (1994)
10.1002/MUS.880140711
Distant effects of locally injected botulinum toxin: A double‐blind study of single fiber EMG changes
D. Lange (1991)
Treatment of tension type headache by local injection of botulinum toxin
Maja Relja (1997)
10.1073/PNAS.96.6.3200
Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.
A. de Paiva (1999)
Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study.
B. Freund (2000)
10.1016/S0264-410X(96)00094-1
Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum.
M. Dertzbaugh (1996)
10.1056/NEJM199907083410201
A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure.
Giuseppe Brisinda (1999)
10.1056/NEJM199801223380402
A comparison of botulinum toxin and saline for the treatment of chronic anal fissure.
G. Maria (1998)
10.1002/(SICI)1097-4598(1997)6+<129::AID-MUS9>3.0.CO;2-B
Botulinum toxin: Historical perspective and potential new indications
J. Jankovic (1997)
10.1002/MDS.870090106
Histologic assessment of dose‐related diffusion and muscle fiber response after therapeutic botulinum a toxin injections
G. Borodic (1994)
10.1016/0002-9394(75)90530-9
Ocular involvement in benign botulism B.
H. König (1975)
Botulinum toxin A inhibits the inflammatory pain in the rat formalin model
ML Cui (2000)
10.3109/00016489309135834
Botulinum A toxin effects on rat jaw muscle spindles.
G. Filippi (1993)
10.1212/WNL.49.3.701
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
M. Lew (1997)
The use of botulinum toxin for anal fissure.
V. Parikh (1997)
10.1056/NEJM199104253241707
Therapeutic uses of botulinum toxin.
J. Jankovic (1991)
Botulinum toxin type A (BTX-A) for migraine: an open label assessment [abstract
W Binder (1998)
10.1128/IAI.57.1.18-22.1989
Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody.
J. Halpern (1989)
10.1016/S0733-8619(18)30311-6
Botulinum toxin therapy.
P. Savino (1991)
10.1111/j.1468-1331.1999.tb00044.x
Prophylactic treatment of chronic tension‐type headache using botulinum toxin type A
J. Smuts (1999)
10.1016/S0306-4522(97)00200-5
Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: ultrastructural and synaptic alterations
A. Pastor (1997)
10.1212/WNL.45.3.506
Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm
T. Mezaki (1995)
10.1212/WNL.46.1.26
Botulinum toxin therapy, immunologic resistance, and problems with available materials
G. Borodic (1996)
10.1001/ARCHOTOL.1988.01860240057024
Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)
A. W. Biglan (1988)
10.1016/S0041-0101(99)00153-1
Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.
M. Welch (2000)
10.1016/0140-6736(93)90109-T
Botulinum toxin for achalasia
P. Pasricha (1993)
10.1212/WNL.41.11.1800
Botulinum‐induced alteration of nerve‐muscle interactions in the human orbicularis oculi following treatment for blepharospasm
K. Alderson (1991)
10.1136/PGMJ.65.762.208
Effect of treatment with botulinum toxin on spasticity.
T. K. Das (1989)
10.1097/01241398-199405000-00005
Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.
L. Koman (1994)
10.1097/00006534-199102000-00010
Botulinum A Toxin for the Treatment of Adult‐Onset Spasmodic Torticollis
G. Borodic (1991)
10.1007/BF02050924
One hundred cases of anal fissure treated with botulin toxin
W. Jost (1997)
10.1007/BF02050639
Use of botulinum toxin in anal fissure
W. Jost (1993)
BOTOX (botulinum toxin type A) purified neurotoxin complex prepared from the new bulk toxin retains the same preclinical
R Aoki (1999)
Treatment of tensiontype headache by local injection of botulinum toxin
M Relja (1997)
10.1136/jnnp.64.5.577
Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A
M. Houser (1998)
10.1097/00000542-199403000-00041
Treatment of myofascial pain with botulinum A toxin.
M. Acquadro (1994)
10.1016/0304-3959(94)90048-5
Botulinum toxin in the treatment of myofascial pain syndrome
W. Cheshire (1994)
10.1002/ANA.410350218
Botulinum toxin‐A improves the rigidity of progressive supranuclear palsy
K. B. Polo (1994)
Dose standardization of botulinum toxin.
P. V. D. van den Bergh (1998)
10.1046/j.1471-4159.1999.0730372.x
Internalization and Proteolytic Action of Botulinum Toxins in CNS Neurons and Astrocytes
C. Verderio (1999)



This paper is referenced by
Derives de toxines clostridiales et methodes de traitement de la douleur
S. Donovan (2001)
10.1590/S0034-70942009000300013
Botulinum toxin in pain treatment.
O. C. G. Colhado (2009)
10.3344/KJP.2005.18.1.29
Botulinum Toxin Type A Therapy in Chronic Headache Patients
D. E. Moon (2005)
10.5173/ceju.2012.03.art12
Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children
Mazen Zeino (2012)
10.1016/J.EUUS.2004.09.004
Botox in Urology: A New Treatment Modality without Limitations?
B. Schurch (2004)
10.2169/INTERNALMEDICINE.46.6416
Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
K. Suzuki (2007)
Efeitos da toxina botulínica do tipo A isolada ou em associação com a finasterida sobre a próstata do cão e rato Sprague-Dawley
G. Q. Mostachio (2012)
10.1111/j.1526-4610.2004.04007.x
Regulation of Calcitonin Gene‐Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy
P. Durham (2004)
10.4321/S1134-80462014000500003
Comparación de resultados obtenidos en el tratamiento del dolor miofascial de la cintura pélvica con toxina botulínica sola y asociada con lidocaína
Ignacio Velázquez Rivera (2014)
10.1016/j.juro.2009.01.117
Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder.
M. Flynn (2009)
10.1016/S1064-7406(03)00070-1
Complications of botulinum toxin A use in facial rejuvenation.
A. Vartanian (2003)
Botulinum toxin treatment in disabling migraine: a randomized, double-blind, placebo-controlled study
M. Aguggia (2008)
10.1097/00002508-200211001-00003
Possible Mechanisms for the Effects of Botulinum Toxin on Pain
J. Arezzo (2002)
Botulinum Therapy for Chronic Migraine
Chumpol Anamnart (2011)
Toxina Botulínica do Tipo A: mecanismo de ação
M Matilde M Spósito (2009)
10.1007/s00415-004-1102-z
Neurobiological basis for the use of botulinum toxin in pain therapy
S. Mense (2004)
10.1016/S0021-5155(02)00683-4
Passive length-tensile properties of extraocular muscles under botulinum toxin type C.
T. Furuse (2003)
10.1007/S11934-002-0081-9
Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction
C. Smith (2002)
BOTULINUM TOXIN : HISTORY AND PHARMACOLOGY
C. Comella (2005)
Unizentrische Kohortenstudie zum integrativen Therapiekonzept bei Kindern mit bilateral spastischer Cerebralparese unter besonderer Berücksichtigung der Adhärenz zu der Behandlung mit Botulinumtoxin
C. Klein (2013)
10.1080/09638280400009360
The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity
A. Suputtitada (2005)
10.1097/01.PHM.0000124444.32257.04
Effects of Botulinum Toxin Type B on Stump Pain and Involuntary Movements of the Stump
U. Kern (2004)
10.1517/14656566.2.12.1985
Botulinum toxin for the treatment of cervical dystonia
J. Jankovic (2001)
10.1007/s00482-003-0202-5
Botulinum-Toxin-A in der Behandlung von Phantomschmerzen
U. Kern (2003)
10.18926/AMO/31693
Botulinum toxin treatment of urethral and bladder dysfunction.
C. Smith (2002)
10.1046/j.1526-4610.43.7s.3.x
Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management
K. Aoki (2003)
10.1016/J.JURO.2007.08.032
Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder.
K. A. Neel (2007)
10.1517/13543784.13.11.1437
The analgesic potential of clostridial neurotoxin derivatives
K. Foster (2004)
10.1159/000069640
Botulinum Toxin in Low Back Pain
W. Jost (2003)
10.1111/j.1469-8749.2005.tb01218.x
Botulinum toxin as a novel treatment for self‐mutilation in Lesch—Nyhan syndrome
E. Dabrowski (2005)
10.3390/toxins9080252
Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Dynamic Equinus Foot Deformity in Children with Cerebral Palsy: A Randomized Controlled Trial
H. J. Chang (2017)
10.1097/JNN.0b013e3181aaa98f
Botox Treatment for Migraine and Chronic Daily Headache in Adolescents
V. Chan (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar